Prostate CancerNCT05690399
Evaluation of Clinical and Pathological Characteristics and Routine Treatment of Patients With Prostate Cancer
An observational study of Prostate Cancer, run by Assiut University.
Trial summary
To evaluate clinical and pathological characteristics and treatment protocol and outcomes of patients with prostate cancer in 2 centers of Asyut from 2013 to 2023 Read more about this study
- Who is it for?
- Ages 40 years and older, men only
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- Radiotherapy
- Type of treatment
- Surgery or procedure
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Jan 2023to Apr 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- Men only
- Adult, Older adult
Study population: Diagnosed as prostate cancer from ( 2013- 2023 ) proved by biopsy - Newly diagnosed/ metastatic at presentation
Who may be able to join
- Male patient , Age ≥ 40 yo
- Diagnosed as prostate cancer from ( 2013- 2023 ) proved by biopsy
- Newly diagnosed/ metastatic at presentation
- ECOG 0-4
Who cannot join
- Having Other types of malignancy.
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Evaluation of Clinical and Pathological Characteristics and Routine Treatment of Patients With Prostate Cancer in 2 Centers in Asyut
To evaluate clinical and pathological characteristics and treatment protocol and outcomes of patients with prostate cancer in 2 centers of Asyut from 2013 to 2023
Read the detailed description
Inclusion criteria :
- Male patient , Age ≥ 40 yo
- Diagnosed as prostate cancer from ( 2013- 2023 ) proved by biopsy in South Egypt Cancer Institute "SECI" \& Asyut clinical oncology department
- Newly diagnosed/ metastatic at presentation
- ECOG 0-4
- Exclusion criteria:
- Having Other types of malignancy.
- Conditions
- Prostate Cancer
- Being tested
- Radiotherapy
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RadiotherapyRadiation
Effect of radiotherapy on patients
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical and pathological characteristics and routine treatment of patients with prostate cancer in 2 centers in Asyut in previous 10 years
Clinical and pathological characteristics and routine treatment of patients with prostate cancer in 2 centers in Asyut in previous 10 years
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jan 2023
- Study startJan 2023 (estimated)
- Primary completionMar 2024 (estimated)
- Study completionApr 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aml Mohamed Haridy, Assiut University
- Investigators
- Assiut University, Principal investigator, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05690399
- Sponsor's protocol ID
- Prostate cancer
- Status last verified
- Jan 2023
- First submitted
- 10 Jan 2023
- Last updated
- 19 Jan 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Clinical and Pathological Characteristics and Routine Treatment of Patients With Prostate Cancer in 2 Centers in Asyut
- ClinicalTrials.gov ID
- NCT05690399
- Acronym / sponsor ID
- Prostate cancer
- Conditions
- Prostate Cancer
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Jan 2023 (estimated)
- Primary completion
- Mar 2024 (estimated)
- Study completion
- Apr 2024 (estimated)
- First posted
- 19 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate clinical and pathological characteristics and treatment protocol and outcomes of patients with prostate cancer in 2 centers of Asyut from 2013 to 2023
Detailed description
Inclusion criteria :
- Male patient , Age ≥ 40 yo
- Diagnosed as prostate cancer from ( 2013- 2023 ) proved by biopsy in South Egypt Cancer Institute "SECI" \& Asyut clinical oncology department
- Newly diagnosed/ metastatic at presentation
- ECOG 0-4
- Exclusion criteria:
- Having Other types of malignancy.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Ages
- 40 years and older
- Sex
- Male only
- Age groups
- Adult, Older adult
- Study population
- Diagnosed as prostate cancer from ( 2013- 2023 ) proved by biopsy - Newly diagnosed/ metastatic at presentation
Key inclusion criteria (4 listed)
- Male patient , Age ≥ 40 yo
- Diagnosed as prostate cancer from ( 2013- 2023 ) proved by biopsy
- Newly diagnosed/ metastatic at presentation
- ECOG 0-4
Key exclusion criteria (1 listed)
- Having Other types of malignancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RadiotherapyEffect of radiotherapy on patients | Radiation | – |
Primary outcome
Clinical and pathological characteristics and routine treatment of patients with prostate cancer in 2 centers in Asyut in previous 10 years
Time frame: Baseline
Clinical and pathological characteristics and routine treatment of patients with prostate cancer in 2 centers in Asyut in previous 10 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jan 2023.
- Cancer Stat Facts: Prostate Cancer \[Internet\]. SEER, 2018.Link provided by the sponsor.
- M Alizadeh, S Alizadeh, Glob J Health Sci, 6: 2014. Survey of clinical and pathological characteristics and outcomes of patients with prostate cancerLink provided by the sponsor.
Related trials for Prostate Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Assiut University principal investigator
Assiut University
Questions about this trial
What is this clinical trial studying?
An observational study of Prostate Cancer, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Aml Haridy (01061119919, Amlmohamed1195@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical and pathological characteristics and routine treatment of patients with prostate cancer in 2 centers in Asyut in previous 10 years (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jan 2023.